可穿戴心脏监测器进入临床试验
Wearable heart monitor moves from lab to clinical trial
澳大利亚初创公司Lubdub开发的新型无胶防水心率监测器在珀斯的一家诊所进行临床试验,该技术可连续监测心脏节律长达14天,数据质量优于传统Holter监测器。
A new lightweight, gel-free and waterproof heart monitor that provides real-time insights into heart health is being trialed at an Australian clinic. Originally invented through research at RMIT University and now being developed by Australian startup Lubdub, the wearable wireless patch continuously tracks the heart's rhythm for up to 14 days—giving doctors the same detailed information as a medical-grade electrocardiogram (ECG) Holter monitor.
Patients prescribed a Holter monitor will wear the prototype ECG patch as part of a trial at Midlands Medical Specialists in Perth, Western Australia.
Designed for use beyond hospitals, the technology aims to make high-quality heart rhythm monitoring more accessible by collecting data as patients go about their daily activities.
RMIT professor and Lubdub co-founder Sharath Sriram said the ECG patch was the first of three heart-monitoring technologies Lubdub planned to bring together in a single software platform, alongside biomarker testing and wearable ultrasound imaging.
The university recently licensed the intellectual property for the ECG and biomarker inventions to the company.
Earlier testing involving healthy volunteers found the prototype was comfortable to wear and produced promising results, Sriram said.
"The flexible sensors make better contact with the skin than those used in traditional Holter monitors," he said.
As a result, the data collected by the patch was 18 times cleaner compared with the traditional Holter monitors.
"By reducing the work needed to generate cardiac reports, the technology could allow the same workforce to monitor up to 85% more patients before other enabling tools like AI are implemented," he said.
The clinical trial will gather evidence to support the technology's further development and potential regulatory approval.
Momentum builds
Sriram said the technology has attracted strong interest from medical experts because of its potential to reduce delays between symptoms and treatment and improve access to cardiac monitoring in both metropolitan and rural and remote Australia.
"Despite the high prevalence of cardiovascular disease—responsible for a third of deaths globally and nearly a quarter in Australia—early symptoms are often missed," he said.
"The majority of heart failure diagnoses and hospital admissions are unplanned and occur in emergency situations, with many patients reporting symptoms for years earlier.
"Our innovation is about simpler and more effective screening, because prevention is better than cure."
The Heart Foundation chose Lubdub as one of its 10 most promising heart health projects for 2026.
Heart health in a box
Lubdub ultimately aims to combine wearable ECG monitoring, noninvasive cardiac biomarker testing and wearable ultrasound imaging into a single platform.
Accessing the right diagnostic tests can still be a lengthy and fragmented process for people with potential heart conditions.
Depending on their symptoms, patients may need ECG monitoring, blood tests or an echocardiogram, often involving different appointments, specialists and facilities.
For Lubdub co-founder and director Nikhilesh Bappoo, the problem is personal.
A few years ago, Bappoo's father suffered a heart attack in Perth and received timely specialist care.
The experience prompted Bappoo to reflect on the more limited access to specialist health care in Mauritius, where he grew up.
"Had it happened there, the outcome could have been very different," he said.
The experience strengthened Bappoo's determination to make heart testing more accessible, particularly where cost, limited infrastructure, shortages of specialists and lengthy waits for results can delay diagnosis and treatment.
From research to commercialization
Lubdub's ongoing partnership with RMIT includes research grants and contracts, as well as access to pilot manufacturing facilities at Discovery to Device.
RMIT's deputy vice chancellor of research and innovation, Distinguished Professor Calum Drummond AO, said the licensing agreement with Lubdub showed how university research could be translated into new products and practical benefits.
"Lubdub is focused on making a real difference to heart health through cutting-edge electronics invented right here at RMIT," he said.
The university will continue working with Lubdub as the company tests and advances the technology toward regulatory approval.
Clinical categories
Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Wearable heart monitor moves from lab to clinical trial (2026, November 19) retrieved 19 November 2026 from https://medicalxpress.com/news/2026-11-wearable-heart-lab-clinical-trial.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com